Robin Hood Ventures

Robin Hood Ventures is a group of angel investors, focused on early-stage, high-growth companies in the Greater Philadelphia region. We help entrepreneurs build great companies, providing capital, mentoring, expertise and connections to help companies reach their potential. Robin Hood generally invests $250k to $500k, and collaborates with angels, institutions and VCs in our network. We invest as a single entity in businesses we know and understand, in a way that gets deals done. Since 1999, we have invested in over 45 companies in industries including software, medical devices, biotech, internet and financial technology.

Donna Cordner

Managing Partner

Allen Fogel

Partner

Sasha Schrode

Partner at Robin Hood Ventures

Ellen Weber

Executive Director

Past deals in Health Care

BiologicsMD

Corporate Round in 2024
BiologicsMD, Inc. is a therapeutic development company based in Fayetteville, Arkansas, established in 2010. The company specializes in creating targeted therapies for hair loss and severe bone disorders. Its product pipeline includes BMD-1141, a hair cycle stimulator aimed at restoring normal hair growth and preventing hair loss by stimulating the hair cycle, and BMD-1231, a bone graft substitute designed for spinal fusion procedures. BiologicsMD focuses on developing recombinant fusion proteins that deliver potent stimulatory effects directly to specific receptors at the site of disease, allowing for sustained therapeutic exposure with either a single dose or infrequent dosing regimens. The company is also exploring various formulation and delivery methods for parenteral, local, and topical administration of its therapies.

Proscia

Series C in 2024
Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.

Illumina Radiopharmaceuticals

Venture Round in 2023
Illumina Radiopharmaceuticals

Cooler Heads

Venture Round in 2023
Cooler Heads is a company that specializes in developing portable scalp cooling systems specifically for chemotherapy patients. Its flagship product, Amma™, is designed to help individuals undergoing cancer treatment maintain their hair, thereby enhancing their sense of identity and control during a challenging time. By cooling the scalp, the system aims to reduce hair loss associated with chemotherapy, allowing patients to manage the physical side effects of treatment more effectively. This approach not only addresses the cosmetic concerns of hair loss but also positively impacts patients' mental health and overall recovery by supporting their emotional well-being throughout the treatment process.

AnaOno

Seed Round in 2022
AnaOno is an apparel brand focused on creating unique intimates and loungewear for women who have undergone breast surgery, including mastectomies and breast reconstructions, often due to cancer diagnoses. The company designs its products to accommodate different breast shapes and surgical needs, crafting wire-free undergarments made from soft materials that prioritize comfort. With an emphasis on feminine details and diverse silhouettes, AnaOno offers a range of options to meet the specific needs of women living with these conditions, ensuring they have access to stylish and functional apparel.

Illumina Radiopharmaceuticals

Venture Round in 2022
Illumina Radiopharmaceuticals

BiologicsMD

Venture Round in 2022
BiologicsMD, Inc. is a therapeutic development company based in Fayetteville, Arkansas, established in 2010. The company specializes in creating targeted therapies for hair loss and severe bone disorders. Its product pipeline includes BMD-1141, a hair cycle stimulator aimed at restoring normal hair growth and preventing hair loss by stimulating the hair cycle, and BMD-1231, a bone graft substitute designed for spinal fusion procedures. BiologicsMD focuses on developing recombinant fusion proteins that deliver potent stimulatory effects directly to specific receptors at the site of disease, allowing for sustained therapeutic exposure with either a single dose or infrequent dosing regimens. The company is also exploring various formulation and delivery methods for parenteral, local, and topical administration of its therapies.

Proscia

Series C in 2022
Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.

Cooler Heads

Seed Round in 2021
Cooler Heads is a company that specializes in developing portable scalp cooling systems specifically for chemotherapy patients. Its flagship product, Amma™, is designed to help individuals undergoing cancer treatment maintain their hair, thereby enhancing their sense of identity and control during a challenging time. By cooling the scalp, the system aims to reduce hair loss associated with chemotherapy, allowing patients to manage the physical side effects of treatment more effectively. This approach not only addresses the cosmetic concerns of hair loss but also positively impacts patients' mental health and overall recovery by supporting their emotional well-being throughout the treatment process.

Proscia

Series B in 2020
Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.

Ophidion

Venture Round in 2019
Ophidion is a biotechnology company that specializes in developing therapeutics for the central nervous system by delivering treatments directly to targeted sites in the brain. Utilizing a Trojan horse strategy, Ophidion exploits an endogenous receptor-mediated transport system to facilitate the intravenous delivery of small molecule drugs and biologics, including gene-silencing therapies. The company focuses on treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its platform is versatile, allowing for the delivery of various drug classes, including oligonucleotides, small interfering RNAs (siRNAs), antibodies, and peptides. Additionally, Ophidion has an advanced program aimed at addressing anxiety-related disorders, which includes a patented companion biomarker diagnostic to identify suitable patient populations for treatment.

Illumina Radiopharmaceuticals

Seed Round in 2019
Illumina Radiopharmaceuticals

Proscia

Series A in 2018
Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.

Proscia

Seed Round in 2016
Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.

Illumina Radiopharmaceuticals

Illumina Radiopharmaceuticals
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.